Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.

JS, Smolen; MC, Genovese; T, Takeuchi; DL, Hyslop; WL, Macias; T, Rooney; L, Chen; CL, Dickson; Camp J, Riddle; TE, Cardillo; T, Ishii; KL, Winthrop

doi:10.3899/jrheum.171361

Public

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.

Shared by NobleBlocks on Sep 15, 2018 • 12:00 AM UTC

Authors:

Smolen JS

Genovese MC

Takeuchi T

Abstract

<h4>Objective</h4>Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA). We evaluated baricitinib's safety profile through 288 weeks (up to September 1, 2016) with an integrated database [8 phase III/II...

Subject

Safety

Rheumatoid arthritis

Clinical Trials

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!